187 related articles for article (PubMed ID: 21482111)
41. End-plate acetylcholinesterase deficiency associated with small nerve terminals and reduced acetylcholine release. A new syndrome.
Engel AG; Lambert EH; Gomez MR
Int J Neurol; 1980; 14(1):73-86. PubMed ID: 6293992
[No Abstract] [Full Text] [Related]
42. Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies.
Slater CR; Young C; Wood SJ; Bewick GS; Anderson LV; Baxter P; Fawcett PR; Roberts M; Jacobson L; Kuks J; Vincent A; Newsom-Davis J
Brain; 1997 Sep; 120 ( Pt 9)():1513-31. PubMed ID: 9313636
[TBL] [Abstract][Full Text] [Related]
43. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies.
Robb SA; Sewry CA; Dowling JJ; Feng L; Cullup T; Lillis S; Abbs S; Lees MM; Laporte J; Manzur AY; Knight RK; Mills KR; Pike MG; Kress W; Beeson D; Jungbluth H; Pitt MC; Muntoni F
Neuromuscul Disord; 2011 Jun; 21(6):379-86. PubMed ID: 21440438
[TBL] [Abstract][Full Text] [Related]
44. End-plate potentials in experimental autoimmune myasthenia gravis in rats.
Lambert EH; Lindstrom JM; Lennon VA
Ann N Y Acad Sci; 1976; 274():300-18. PubMed ID: 1066990
[TBL] [Abstract][Full Text] [Related]
45. Neuromuscular junction abnormalities in DNM2-related centronuclear myopathy.
Gibbs EM; Clarke NF; Rose K; Oates EC; Webster R; Feldman EL; Dowling JJ
J Mol Med (Berl); 2013 Jun; 91(6):727-37. PubMed ID: 23338057
[TBL] [Abstract][Full Text] [Related]
46. Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome.
Gomez CM; Maselli RA; Groshong J; Zayas R; Wollmann RL; Cens T; Charnet P
J Neurosci; 2002 Aug; 22(15):6447-57. PubMed ID: 12151524
[TBL] [Abstract][Full Text] [Related]
47. Neuromuscular transmission in neonatal mice injected with serum globulin of myasthenia gravis patients.
Pagala MK; Tada S; Namba T; Grob D
Neurology; 1982 Jan; 32(1):12-7. PubMed ID: 6275304
[TBL] [Abstract][Full Text] [Related]
48. Activity-dependent presynaptic regulation of quantal size at the mammalian neuromuscular junction in vivo.
Wang X; Li Y; Engisch KL; Nakanishi ST; Dodson SE; Miller GW; Cope TC; Pinter MJ; Rich MM
J Neurosci; 2005 Jan; 25(2):343-51. PubMed ID: 15647477
[TBL] [Abstract][Full Text] [Related]
49. Synaptic Deficits at Neuromuscular Junctions in Two Mouse Models of Charcot-Marie-Tooth Type 2d.
Spaulding EL; Sleigh JN; Morelli KH; Pinter MJ; Burgess RW; Seburn KL
J Neurosci; 2016 Mar; 36(11):3254-67. PubMed ID: 26985035
[TBL] [Abstract][Full Text] [Related]
50. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.
Jungbluth H; Zhou H; Sewry CA; Robb S; Treves S; Bitoun M; Guicheney P; Buj-Bello A; Bönnemann C; Muntoni F
Neuromuscul Disord; 2007 Apr; 17(4):338-45. PubMed ID: 17376685
[TBL] [Abstract][Full Text] [Related]
51. Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome.
Gomez CM; Maselli R; Williams JM; Bhattacharyya BB; Wollmann RL; Day JW
Ann N Y Acad Sci; 1998 May; 841():167-80. PubMed ID: 9668235
[No Abstract] [Full Text] [Related]
52. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies.
Toussaint A; Cowling BS; Hnia K; Mohr M; Oldfors A; Schwab Y; Yis U; Maisonobe T; Stojkovic T; Wallgren-Pettersson C; Laugel V; Echaniz-Laguna A; Mandel JL; Nishino I; Laporte J
Acta Neuropathol; 2011 Feb; 121(2):253-66. PubMed ID: 20927630
[TBL] [Abstract][Full Text] [Related]
53. Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances.
Gómez-Oca R; Cowling BS; Laporte J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768808
[TBL] [Abstract][Full Text] [Related]
54. Release properties of isolated neuromuscular boutons of the garter snake.
Wilkinson RS; Son YJ; Lunin SD
J Physiol; 1996 Sep; 495 ( Pt 2)(Pt 2):503-14. PubMed ID: 8887760
[TBL] [Abstract][Full Text] [Related]
55. Sporadic centronuclear myopathy with muscle pseudohypertrophy, neutropenia, and necklace fibers due to a DNM2 mutation.
Liewluck T; Lovell TL; Bite AV; Engel AG
Neuromuscul Disord; 2010 Dec; 20(12):801-4. PubMed ID: 20817456
[TBL] [Abstract][Full Text] [Related]
56. Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients.
Abath Neto O; Moreno CAM; Malfatti E; Donkervoort S; Böhm J; Guimarães JB; Foley AR; Mohassel P; Dastgir J; Bharucha-Goebel DX; Monges S; Lubieniecki F; Collins J; Medne L; Santi M; Yum S; Banwell B; Salort-Campana E; Rendu J; Fauré J; Yis U; Eymard B; Cheraud C; Schneider R; Thompson J; Lornage X; Mesrob L; Lechner D; Boland A; Deleuze JF; Reed UC; Oliveira ASB; Biancalana V; Romero NB; Bönnemann CG; Laporte J; Zanoteli E
Neuromuscul Disord; 2017 Nov; 27(11):975-985. PubMed ID: 28818389
[TBL] [Abstract][Full Text] [Related]
57. Ultrastructural localization of acetylcholine receptor at the motor endplate: myasthenia gravis and other neuromuscular diseases.
Tsujihata M; Hazama R; Ishii N; Ide Y; Takamori M
Neurology; 1980 Nov; 30(11):1203-11. PubMed ID: 7191515
[TBL] [Abstract][Full Text] [Related]
58. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome.
Ohno K; Engel AG; Shen XM; Selcen D; Brengman J; Harper CM; Tsujino A; Milone M
Am J Hum Genet; 2002 Apr; 70(4):875-85. PubMed ID: 11791205
[TBL] [Abstract][Full Text] [Related]
59. Congenital myasthenia: further evidence of disease heterogeneity.
Lecky BR; Morgan-Hughes JA; Murray NM; Landon DN; Wray D; Prior C
Muscle Nerve; 1986; 9(3):233-42. PubMed ID: 3010100
[TBL] [Abstract][Full Text] [Related]
60. Immunopathologic events at the endplate in myasthenia gravis.
Ashizawa T; Appel SH
Springer Semin Immunopathol; 1985; 8(3):177-96. PubMed ID: 2413561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
